Loading...
Indian Pharmaceutical Exporter · #6 for Carvedilol · $1.4M export value · DGFT Verified
Cipla Limited is the #6 Indian exporter of Carvedilol with $1.4M in export value and 28 verified shipments. Cipla Limited holds a 1.4% market share in Carvedilol exports across 4 countries. The company exports 98 pharmaceutical products worth $1.1B across 26 therapeutic categories.
| $12.7K |
| 3 |
| 2.7% |
| TANZANIA | $5.3K | 1 | 1.1% |
Cipla Limited exports Carvedilol to 6 countries. The largest destination is YEMEN, DEMOCRATIC accounting for 41.7% of Cipla Limited's Carvedilol shipments, followed by YEMEN (28.3%) and GUATEMALA (23.0%). These destinations reflect Cipla Limited's established distribution network and regulatory approvals in key markets.
| Buyer | Country | Value | Orders |
|---|---|---|---|
| CIPLAMEDICA PHARMACEUTICAL INDUSTRI | YEMEN | $259.6K | 10 |
| PROFON S A | GUATEMALA | $64.9K | 4 |
| MEDICA PHARMACEUTICAL INDUSTRIES L | YEMEN | $40.6K | 2 |
| CIPLAMEDICA PHARMACEUTICAL INDUSTRI ANAA | YEMEN | $35.6K | 4 |
| PROFON SA | GUATEMALA | $31.2K | 2 |
| PROFON SA, | GAUTEMALA | $15.4K | 1 |
| PROFON SA NIT 3739739-7 2 | GUATEMALA | $14.0K | 1 |
| PHYSICIANS PHARMACEUTICALS LTD, | TRINIDAD & TOBAGO | $12.7K | 3 |
| JD PHARMACY | TANZANIA | $5.3K | 1 |
Cipla Limited supplies Carvedilol to 9 buyers globally. The largest buyer is CIPLAMEDICA PHARMACEUTICAL INDUSTRI (YEMEN), followed by PROFON S A (GUATEMALA) and MEDICA PHARMACEUTICAL INDUSTRIES L (YEMEN). These buyers represent pharmaceutical distributors, hospital groups, and government procurement agencies in their respective markets.
India exported $67.1M worth of Carvedilol through 4,750 shipments from 242 suppliers to 98 countries, serving 529 buyers globally. Cipla Limited contributes $1.4M to this total, accounting for 1.4% of India's Carvedilol exports. Cipla Limited ships Carvedilol to 6 countries through 9 buyers.
Cipla Limited's average Carvedilol shipment value is $50.0K per consignment, based on 28 shipments totaling $1.4M. The largest destination is YEMEN, DEMOCRATIC (41.7% of Cipla Limited's Carvedilol exports).
Cipla Limited ranks #6 among 242 Indian Carvedilol exporters with a 1.4% market share. The top 3 exporters are ZYDUS LIFESCIENCES LIMITED ($21.9M), GLENMARK PHARMACEUTICALS LIMITED ($8.4M), AUROBINDO PHARMA LTD ($7.6M). Cipla Limited processed 28 shipments to 4 destination countries.
| Product Description / Formulation | Value | Shipments |
|---|---|---|
| CARVEDILOL 12.5 MG TABLET DOCUMENT QTY 29 | $80.6K | 5 |
| CARLOC 6.25 TABLET (CARVEDILOL TABLETS 6.25 MG) (INV.QTY.6720 PACK 10X10S=672000 NOS) | $50.0K | 1 |
| CARLOC 6.25 TABLET (CARVEDILOL TABLETS 6.25 MG) (INV.QTY.6440 PACK 10X10S=644000 NOS) | $50.0K | 1 |
| CARLOC 6.25 TABLET (CARVEDILOL TABLETS 6.25 MG) (INV.QTY.3460 PACK 10X10S=346000 NOS) | $50.0K | 1 |
| CARLOC 6.25 TABLET (CARVEDILOL TABLETS 6.25 MG) (INV.QTY.3163 PACK 10X10S=316300 NOS) | $50.0K | 1 |
| CARLOC 6.25 TABLET (CARVEDILOL TABLETS 6.25 MG) ( INV. QTY. 6720 PACK 10 X 10'S = 672000 NOS ) | $40.6K | 2 |
| CARLOC 12.5 TABLET CARVEDILOL TABLETS 12.5MG DOCUMENT QTY.2984 PACK 10 X 10S =298400 NOS | $21.1K | 1 |
| CARVEDILOL 12.5 MG TABLET DOCUMENT QTY. 288 | $15.4K | 1 |
| CARVEDILOL 12.5 MG TABLET (INV. QTY2946 | $15.4K | 1 |
| CARVEDILOL 12.5MG TABLETS 29100PACKS X3 | $14.0K | 1 |
Cipla Limited exports 23 distinct Carvedilol formulations including tablets, capsules, syrups, and combination drugs. The top formulation is CARVEDILOL 12.5 MG TABLET DOCUMENT QTY 29 with 5 shipments worth $80.6K.
Exporters ranked immediately above and below #6 by export value
| # | Supplier | Export Value | Shipments | Countries | Avg/Shipment |
|---|---|---|---|---|---|
| 12 | SANDOZ PRIVATE LIMITED | $1.5M | 69 | 2 | $21.2K |
| 2 | CARITAS HEALTHCARE PRIVATE LIMITED | $1.4M | 29 | 1 | $50.0K |
| 6 | CIPLA LIMITED ★ | $1.4M | 28 | 4 | $50.0K |
| 13 | TORRENT PHARMACEUTICALS LTD | $1.1M | 93 | 10 | $12.0K |
| 15 | AMNEAL PHARMACEUTICALS PRIVATE LIMITED | $812.6K | 24 | 1 | $33.9K |
Cipla Limited ranks #6 among 242 Indian Carvedilol exporters. Average shipment value of $50.0K compared to the market average of $277.3K. The closest competitors by value are SANDOZ PRIVATE LIMITED and CARITAS HEALTHCARE PRIVATE LIMITED.
| Port | Shipments | % Share |
|---|---|---|
| NHAVA SHEVA SEA (INNSA1) | 506 | 10.7% |
| SAHAR AIR | 482 | 10.1% |
| DELHI AIR CARGO ACC (INDEL4) | 405 | 8.5% |
| SAHAR AIR CARGO ACC (INBOM4) | 358 | 7.5% |
| MUNDRA SEA | 305 | 6.4% |
| DELHI AIR | 288 | 6.1% |
| HYDERABAD ICD (INSNF6) | 253 | 5.3% |
| JNPT/ NHAVA SHEVA SEA | 238 | 5.0% |
Cipla's export operations are currently navigating a complex geopolitical landscape. The Israel-Iran conflict has led to disruptions in Red Sea shipping routes, resulting in increased freight costs and extended transit times. These challenges are particularly acute for time-sensitive pharmaceutical shipments, necessitating strategic adjustments in logistics and supply chain management.
In the United States, recent import policies, including the imposition of 100% tariffs on branded or patented pharmaceutical products effective October 2025, have introduced additional hurdles for Indian exporters. While generic drugs, a significant component of Cipla's portfolio, may be less affected, the overall trade environment demands vigilance and adaptability. Conversely, the India-European Union Free Trade Agreement, concluded in January 2026, offers a promising avenue for Cipla. The agreement aims to eliminate tariffs on pharmaceuticals, potentially enhancing Cipla's competitiveness in the European market and offsetting challenges faced in other regions.
Maintaining stringent quality standards is paramount for Cipla, given the diverse regulatory environments across its export markets. The company has demonstrated a strong commitment to compliance, as evidenced by the U.S. Food and Drug Administration's (FDA) classification of its Bengaluru facility as Voluntary Action Indicated (VAI) in October 2025. This classification is crucial for sustaining and expanding Cipla's presence in the U.S. market. Additionally, the European Union's evolving regulatory framework, including the Falsified Medicines Directive, necessitates continuous adaptation to ensure compliance and maintain market access.
Cipla Limited exports 98 products worth $1.1B. Beyond Carvedilol, top products include Fluticasone, Amlodipine, Salbutamol, Telmisartan, Salmeterol. View the complete Cipla Limited profile for full portfolio analysis.
Latest developments and market context
Detailed market intelligence for Carvedilol — including regulatory updates, trade policy changes, and competitive landscape analysis — will be available in an upcoming update. This section will feature AI-researched insights from verified industry sources, government notifications, and market reports.
Verify manufacturer licensing and export certifications with the official agencies above.
Pharmaceutical Export-Import Analyst & Trade Intelligence Expert
Suresh Sormare is a pharmaceutical export-import analyst with deep expertise in Indian Customs (DGFT) data, HS code classification, and global pharmaceutical supply chains. His analysis covers 10M+ shipment records across 150+ countries and is used by manufacturers, procurement agencies, and trade consultants worldwide. Suresh specializes in identifying verified suppliers and buyers from customs records, mapping bilateral pharmaceutical trade corridors, analyzing tariff structures and regulatory frameworks across 170+ destination markets, and benchmarking competitive positioning for finished pharmaceutical formulations. His methodology combines granular customs transaction data with regulatory intelligence from FDA, EMA, WHO, CDSCO, and 40+ national drug authorities to deliver actionable trade insights for the pharmaceutical formulations sector.
linkedin.com/in/sureshsormareAll trade data is sourced from Indian Customs (DGFT) official shipping bill records — the authoritative government database for India's pharmaceutical trade. Each verified record contains exporter name, consignee (buyer) name, detailed product description, quantity, declared FOB value (USD), port of loading, destination country, and shipment date.
Government-Sourced Data
Official DGFT customs records
Transparent Methodology
Calculations fully disclosed above
Global Coverage
Exports to 98+ countries, 529+ buyers
Expert-Reviewed
Analyzed by pharmaceutical trade specialists
Access shipment-level details, pricing data, buyer connections, and competitive analysis for Cipla Limited's Carvedilol exports. TransData Nexus provides verified Indian Customs (DGFT) data trusted by pharmaceutical trade professionals worldwide.
Cipla Limited
Full Company Profile →
98 products · $1.1B total trade · 26 categories
Access shipment-level records, pricing trends, and buyer contacts for Cipla Limited.
Request DemoView Pricing →Trade data sourced from Indian Customs (DGFT) export shipment records. Values represent FOB export value in USD. Market share calculated relative to total Indian pharmaceutical exports for Carvedilol. For current shipment-level data, contact TransData Nexus.